Literature DB >> 21387461

An automated database case definition for serious bleeding related to oral anticoagulant use.

Andrew Cunningham1, C Michael Stein, Cecilia P Chung, James R Daugherty, Walter E Smalley, Wayne A Ray.   

Abstract

PURPOSE: Bleeding complications are a serious adverse effect of medications that prevent abnormal blood clotting. To facilitate epidemiologic investigations of bleeding complications, we developed and validated an automated database case definition for bleeding-related hospitalizations.
METHODS: The case definition utilized information from an in-progress retrospective cohort study of warfarin-related bleeding in Tennessee Medicaid enrollees 30 years of age or older. It identified inpatient stays during the study period of January 1990 to December 2005 with diagnoses and/or procedures that indicated a current episode of bleeding. The definition was validated by medical record review for a sample of 236 hospitalizations.
RESULTS: We reviewed 186 hospitalizations that had medical records with sufficient information for adjudication. Of these, 165 (89%, 95%CI: 83-92%) were clinically confirmed bleeding-related hospitalizations. An additional 19 hospitalizations (10%, 7-15%) were adjudicated as possibly bleeding-related. Of the 165 clinically confirmed bleeding-related hospitalizations, the automated database and clinical definitions had concordant anatomical sites (gastrointestinal, cerebral, genitourinary, other) for 163 (99%, 96-100%). For those hospitalizations with sufficient information to distinguish between upper/lower gastrointestinal bleeding, the concordance was 89% (76-96%) for upper gastrointestinal sites and 91% (77-97%) for lower gastrointestinal sites.
CONCLUSION: A case definition for bleeding-related hospitalizations suitable for automated databases had a positive predictive value of between 89% and 99% and could distinguish specific bleeding sites.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21387461      PMCID: PMC3365595          DOI: 10.1002/pds.2109

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  24 in total

1.  Population-based studies of adverse drug effects.

Authors:  Wayne A Ray
Journal:  N Engl J Med       Date:  2003-10-23       Impact factor: 91.245

2.  Use of Medicaid data for pharmacoepidemiology.

Authors:  W A Ray; M R Griffin
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

3.  Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study.

Authors:  Wayne A Ray; Katherine T Murray; Marie R Griffin; Cecilia P Chung; Walter E Smalley; Kathi Hall; James R Daugherty; Lisa A Kaltenbach; C Michael Stein
Journal:  Ann Intern Med       Date:  2010-03-16       Impact factor: 25.391

4.  Methodological issues in evaluating expanded Medicaid coverage for pregnant women.

Authors:  J M Piper; W A Ray; M R Griffin; R Fought; J R Daughtery; E Mitchel
Journal:  Am J Epidemiol       Date:  1990-09       Impact factor: 4.897

5.  Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons.

Authors:  M R Griffin; W A Ray; W Schaffner
Journal:  Ann Intern Med       Date:  1988-09-01       Impact factor: 25.391

6.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.

Authors:  Agnes Y Y Lee; Mark N Levine; Ross I Baker; Chris Bowden; Ajay K Kakkar; Martin Prins; Frederick R Rickles; Jim A Julian; Susan Haley; Michael J Kovacs; Michael Gent
Journal:  N Engl J Med       Date:  2003-07-10       Impact factor: 91.245

7.  Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease.

Authors:  R I Shorr; W A Ray; J R Daugherty; M R Griffin
Journal:  Arch Intern Med       Date:  1993-07-26

8.  Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data.

Authors:  Christianne L Roumie; Edward Mitchel; Patricia S Gideon; Cristina Varas-Lorenzo; Jordi Castellsague; Marie R Griffin
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-01       Impact factor: 2.890

9.  Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

Authors:  Charles W Francis; Scott D Berkowitz; Philip C Comp; Jay R Lieberman; Jeffrey S Ginsberg; Guy Paiement; Gary R Peters; Anne W Roth; Jennifer McElhattan; Clifford W Colwell
Journal:  N Engl J Med       Date:  2003-10-30       Impact factor: 91.245

10.  Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.

Authors:  S Bertil Olsson
Journal:  Lancet       Date:  2003-11-22       Impact factor: 79.321

View more
  108 in total

1.  Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding.

Authors:  Wayne A Ray; Cecilia P Chung; Katherine T Murray; Walter E Smalley; James R Daugherty; William D Dupont; C Michael Stein
Journal:  JAMA       Date:  2018-12-04       Impact factor: 56.272

2.  Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans.

Authors:  Michael A Lane; Angelique Zeringue; Jay R McDonald
Journal:  Am J Med       Date:  2014-03-19       Impact factor: 4.965

3.  Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States.

Authors:  Konstantinos C Siontis; Xiaosong Zhang; Ashley Eckard; Nicole Bhave; Douglas E Schaubel; Kevin He; Anca Tilea; Austin G Stack; Rajesh Balkrishnan; Xiaoxi Yao; Peter A Noseworthy; Nilay D Shah; Rajiv Saran; Brahmajee K Nallamothu
Journal:  Circulation       Date:  2018-10-09       Impact factor: 29.690

4.  Association of Proton Pump Inhibitors With Reduced Risk of Warfarin-Related Serious Upper Gastrointestinal Bleeding.

Authors:  Wayne A Ray; Cecilia P Chung; Katherine T Murray; Walter E Smalley; James R Daugherty; William D Dupont; C Michael Stein
Journal:  Gastroenterology       Date:  2016-09-14       Impact factor: 22.682

5.  Warfarin use and the risk of stroke, bleeding, and mortality in older adults on dialysis with incident atrial fibrillation.

Authors:  Jingwen Tan; Sunjae Bae; Jodi B Segal; Junya Zhu; G Caleb Alexander; Dorry L Segev; Mara McAdams-DeMarco
Journal:  Nephrology (Carlton)       Date:  2019-02       Impact factor: 2.506

6.  Comparative Safety and Effectiveness of Direct-Acting Oral Anticoagulants Versus Warfarin: a National Cohort Study of Nursing Home Residents.

Authors:  Matthew Alcusky; Jennifer Tjia; David D McManus; Anne L Hume; Marc Fisher; Kate L Lapane
Journal:  J Gen Intern Med       Date:  2020-04-06       Impact factor: 5.128

7.  Identifying Patients With High Data Completeness to Improve Validity of Comparative Effectiveness Research in Electronic Health Records Data.

Authors:  Kueiyu Joshua Lin; Daniel E Singer; Robert J Glynn; Shawn N Murphy; Joyce Lii; Sebastian Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2017-10-10       Impact factor: 6.875

Review 8.  Developing a Conversation Aid to Support Shared Decision Making: Reflections on Designing Anticoagulation Choice.

Authors:  Claudia L Zeballos-Palacios; Ian G Hargraves; Peter A Noseworthy; Megan E Branda; Marleen Kunneman; Bruce Burnett; Michael R Gionfriddo; Christopher J McLeod; Haeshik Gorr; Juan Pablo Brito; Victor M Montori
Journal:  Mayo Clin Proc       Date:  2019-01-11       Impact factor: 7.616

9.  Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin.

Authors:  Erin R Weeda; Philip S Wells; W Frank Peacock; Gregory J Fermann; Christopher W Baugh; Veronica Ashton; Concetta Crivera; Peter Wildgoose; Jeff R Schein; Craig I Coleman
Journal:  Intern Emerg Med       Date:  2016-10-18       Impact factor: 3.397

10.  Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study.

Authors:  Sylvie Perreault; Payman Shahabi; Robert Côté; Stéphanie Dumas; Étienne Rouleau-Mailloux; Yassamin Feroz Zada; Sylvie Provost; Ian Mongrain; Marc Dorais; Thao Huynh; Simon Kouz; Ariel Diaz; Mark Blostein; Simon de Denus; Jacques Turgeon; Jeffrey Ginsberg; Jacques Lelorier; Lyne Lalonde; Lambert Busque; Jeannine Kassis; Mario Talajic; Jean-Claude Tardif; Marie-Pierre Dubé
Journal:  Clin Cardiol       Date:  2018-05-15       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.